CIRP regulates BEV-induced cell migration in gliomas

PURPOSE: A better understanding of the underlying molecular mechanisms in treatment failure of bevacizumab (BEV) for malignant glioma would contribute to overcome therapeutic resistance. METHODS: Here, we used a quantitative proteomic method to identify molecular signatures of glioblastoma cell afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yu-Xiao, Zhou, Jun-Nian, Liu, Ke-Hui, Fu, Xiang-pin, Zhang, Zhi-Wen, Zhang, Qin-Hong, Yue, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417006/
https://www.ncbi.nlm.nih.gov/pubmed/30881126
http://dx.doi.org/10.2147/CMAR.S191249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417006/
https://www.ncbi.nlm.nih.gov/pubmed/30881126
http://dx.doi.org/10.2147/CMAR.S191249

Ejemplares similares